List view / Grid view
3 March 2016 | By Victoria White
In a study, some 67% of 347 women given palbociclib plus fulvestrant showed clinical benefit compared with 40% of 174 women given placebo plus fulvestrant...
1 March 2016 | By Victoria White
The breast cancer treatment pipeline’s exceptional levels of activity and innovation may significantly alter the clinical and commercial landscape, says GBI Research...
23 February 2016 | By Victoria White
Ibrance is approved for the treatment of HR+, HER2- advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy...
17 February 2016 | By Victoria White
Eisai and PIQUR Therapeutics are to collaborate to conduct the Phase I/IIb clinical study of PIQUR’s PQR309 in combination with Eisai’s eribulin...
16 February 2016 | By Victoria White
Scientists have developed a test called the Ecosystem Diversity Index which combines methods used by ecologists with a powerful cancer imaging technique...
5 January 2016 | By Victoria White
GBI Research states that this strong growth will be primarily due to substantial increases in the prevalence of breast cancer, with rates of the disease expected to rise over the forecast period due to an aging population, changing lifestyles and higher survival rates...
17 December 2015 | By Victoria White
Genomic Health has announced results from multiple Oncotype DX breast cancer test studies that reconfirm the Oncotype DX test accurately predicts clinical outcomes in patients with early-stage invasive breast cancer...
11 December 2015 | By Victoria White
New data supports the previously shown ability of Eisai’s Halaven (eribulin) to reverse epithelial-to-mesenchymal transition...
1 December 2015 | By Victoria White
The assay has been selected by the International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG) to be part of a trial studying the effects of palbociclib in breast cancer...
17 November 2015 | By Victoria White
NICE has published final draft guidance not recommending the use of Kadcyla as a treatment for a type of advanced breast cancer because the price is too high...
21 October 2015 | By Victoria White
Research has found that women whose breast cancer had begun to spread and who tested positive in the αB-crystallin test were three times more likely to have disease that spread to the brain...
8 October 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation to abemaciclib for patients with refractory HR+ advanced or metastatic breast cancer...
29 September 2015 | By Victoria White
The Oncoptye DX test could prevent patients from the side effects of unnecessary chemotherapy treatment, and save NHS England up to £5 million per year...
26 August 2015 | By Victoria White
Alliance Foundation Trials, the Austrian Breast & Colorectal Cancer Study Group and Pfizer have launched the Palbociclib Collaborative Adjuvant Study...
21 August 2015 | By Victoria White
The EMA has validated for review a MAA for Ibrance in combination with endocrine therapy for the treatment of HR+/HER2- metastatic breast cancer...
